Alnylam: Q4 Earnings Snapshot

SelfRugger · 2026-03-06T23:47:47+00:00

Alnylam Pharmaceuticals reported a Q4 net income of $111.5 million, exceeding expectations, although revenue of $1.1 billion fell short. For the year, profits totaled $313.7 million, with shares down 19% in 2026 but up 20% over the last year.

SelfRugger

2026-03-06 23:47:47

Abstract generation in progress

Alnylam: Q4 Earnings Snapshot

Associated Press Finance

Thu, February 12, 2026 at 10:22 PM GMT+9 1 min read

In this article:

ALNY

-0.22%

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported fourth-quarter net income of $111.5 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 82 cents. Earnings, adjusted for stock option expense and non-recurring costs, were $1.25 per share.

The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.16 per share.

The RNA interference drug developer posted revenue of $1.1 billion in the period, which fell short of Street forecasts. Ten analysts surveyed by Zacks expected $1.14 billion.

For the year, the company reported net income of $313.7 million, or $2.33 per share, swinging to a profit in the period. Revenue was reported as $3.71 billion.

Alnylam shares have fallen 19% since the beginning of the year. The stock has climbed 20% in the last 12 months.

This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on ALNY at

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes